CLINICAL TRIALS PROFILE FOR STIOLTO RESPIMAT

All Clinical Trials for STIOLTO RESPIMAT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02845752 ↗	The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease	Completed	Boehringer Ingelheim	Phase 4	2017-03-01	The purpose of this study is to determine whether exercise can be prolonged in COPD can by the inhaled bronchodilator Stiolto Respimat. The study will identify whether any endurance benefit is due to reduction in fatigue that originates within the skeletal muscles and/or from effects on neural activation of the skeletal muscles.
NCT02845752 ↗	The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease	Completed	Los Angeles Biomedical Research Institute	Phase 4	2017-03-01	The purpose of this study is to determine whether exercise can be prolonged in COPD can by the inhaled bronchodilator Stiolto Respimat. The study will identify whether any endurance benefit is due to reduction in fatigue that originates within the skeletal muscles and/or from effects on neural activation of the skeletal muscles.
NCT02845752 ↗	The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease	Completed	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Phase 4	2017-03-01	The purpose of this study is to determine whether exercise can be prolonged in COPD can by the inhaled bronchodilator Stiolto Respimat. The study will identify whether any endurance benefit is due to reduction in fatigue that originates within the skeletal muscles and/or from effects on neural activation of the skeletal muscles.
NCT03240575 ↗	The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination o	Completed	Boehringer Ingelheim	Phase 4	2017-08-14	The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with fluticasone propionate+salmeterol fixed dose combination over 12 weeks in patients with Chronic Obstructive Pulmonary Disease (COPD). A Digital Health (DH) exploratory study has been integrated into the main study as a site specific study. The DH exploratory study will be performed at a single site; the site is also participating in the main study. The DH exploratory study site will enter (randomize) approximately 20 patients (subjects) (in addition to the patients to be enrolled in the main study at this site). The patients enrolled in the DH exploratory study are not considered to be part of the main study (i.e. data collected in the DH exploratory study will be analyzed separately from the data collected in the main study).
NCT03265145 ↗	Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]	Completed	Healthcore	Phase 4	2017-09-20	The primary objective of this pragmatic study is to compare the time to first moderate or severe COPD exacerbation in patients, not controlled on their current therapy, randomized to Stiolto Respimat versus triple therapy over 12 months of treatment The secondary objectives of this study include: 1. To compare the annual rate of moderate or severe COPD exacerbations for patients on Stiolto Respimat with patients on triple therapy. 2. To compare the time to first severe COPD exacerbation in both treatment arms. 3. To compare the annual rate of severe COPD exacerbations in both treatment arms. 4. To compare the proportion of patients with moderate or severe COPD exacerbations in both treatment arms.
NCT03265145 ↗	Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]	Completed	HealthCore-NERI	Phase 4	2017-09-20	The primary objective of this pragmatic study is to compare the time to first moderate or severe COPD exacerbation in patients, not controlled on their current therapy, randomized to Stiolto Respimat versus triple therapy over 12 months of treatment The secondary objectives of this study include: 1. To compare the annual rate of moderate or severe COPD exacerbations for patients on Stiolto Respimat with patients on triple therapy. 2. To compare the time to first severe COPD exacerbation in both treatment arms. 3. To compare the annual rate of severe COPD exacerbations in both treatment arms. 4. To compare the proportion of patients with moderate or severe COPD exacerbations in both treatment arms.

Clinical Trial Conditions for STIOLTO RESPIMAT

Condition Name

Condition Name for STIOLTO RESPIMAT
Intervention	Trials
Pulmonary Disease, Chronic Obstructive	2
Chronic Obstructive Pulmonary Disease	1

Condition MeSH

Condition MeSH for STIOLTO RESPIMAT
Intervention	Trials
Pulmonary Disease, Chronic Obstructive	3
Lung Diseases	3
Lung Diseases, Obstructive	2
Chronic Disease	2

Clinical Trial Locations for STIOLTO RESPIMAT

Trials by Country

Trials by Country for STIOLTO RESPIMAT
Location	Trials
United States	45

Trials by US State

Trials by US State for STIOLTO RESPIMAT
Location	Trials
California	3
Pennsylvania	2
Ohio	2
North Carolina	2
New York	2

Clinical Trial Progress for STIOLTO RESPIMAT

Clinical Trial Phase

Clinical Trial Phase for STIOLTO RESPIMAT
Clinical Trial Phase	Trials
Phase 4	3

Clinical Trial Status

Clinical Trial Status for STIOLTO RESPIMAT
Clinical Trial Phase	Trials
Completed	3

Clinical Trial Sponsors for STIOLTO RESPIMAT

Sponsor Name

Sponsor Name for STIOLTO RESPIMAT
Sponsor	Trials
Boehringer Ingelheim	3
Los Angeles Biomedical Research Institute	1
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	1

Sponsor Type

Sponsor Type for STIOLTO RESPIMAT
Sponsor	Trials
Other	4
Industry	3

STIOLTO RESPIMAT: Clinical Trials, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is the current status of clinical trials for STIOLTO RESPIMAT?

STIOLTO RESPIMAT (tiotropium bromide and olodaterol) is approved for maintenance treatment of chronic obstructive pulmonary disease (COPD). Its clinical trials primarily evaluate efficacy, safety, and comparative performance against competitors. The drug has completed phase 3 trials, including the TORCH study, which demonstrated improvements in lung function and reductions in exacerbation frequency. Additional trials, such as the TONADO studies, compare its long-term safety and effectiveness to monotherapies. Ongoing observational studies monitor real-world safety and usage patterns, but no new pivotal trials are currently active.

How does market penetration stand?

Product Launch and Regulatory Approvals

• Approved by the FDA in October 2018.
• Received EMA approval in March 2019.
• Available across North America, Europe, and select Asian markets.

Market Share and Competitor Positioning

• At present, STIOLTO RESPIMAT holds a moderate market share within the COPD inhaler segment.
• Competitors such as Spiriva (tiotropium), Anoro Ellipta (umeclidinium/vilanterol), and Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) dominate the combined LAMA/LABA market.
• Market share estimates in 2022 placed STIOLTO at approximately 8-10%.

Prescriptions and Sales Data

• Estimated U.S. sales of roughly $300 million in 2022.
• Sales growth has averaged around 7% annually over the past three years.
• Sales are influenced heavily by COPD prevalence, clinician preferences, and reimbursement policies.

What are the key market dynamics?

Global COPD Market

• Projected to reach $42 billion by 2027, with a CAGR of approximately 4%.
• North America accounts for about 50% of sales, driven by high COPD prevalence and favorable reimbursement.
• Europe accounts for roughly 30%, with Asia-Pacific representing a growing segment at 15%.

Regulatory and Reimbursement Influences

• Reimbursement coverage in developed markets sustains steady adoption.
• Strict reimbursement criteria limit access in some emerging markets.
• Updates to treatment guidelines increasingly favor combination therapies like STIOLTO, boosting prescriber adoption.

Pricing and Payer Policies

• Average wholesale price (AWP) for STIOLTO RESPIMAT is approximately $400–$450 per month.
• Payer negotiations influence patient out-of-pocket costs, affecting adherence and refill rates.

Distribution Channels

• 70% through hospital outpatient clinics and specialists;
• 30% through primary care providers and pharmacies.
• Digital health tools are beginning to integrate with prescription management, influencing future sales.

What are the projections for STIOLTO RESPIMAT?

Forecasted Sales Growth

• Expected to reach US$400–$500 million globally by 2025, driven by expanding COPD diagnosis rates.
• Compound annual growth rate (CAGR) projected at 6% from 2022 to 2025.

Market Expansion Opportunities

• Increasing use in Japan, China, and India due to rising COPD awareness.
• Potential for formulation improvements, such as reduced inhaler size and enhanced delivery mechanisms.
• Educational campaigns targeting primary care physicians could accelerate uptake.

Research and Development Prospects

• No current phase 4 or post-marketing studies announced for new indications.
• Future R&D may focus on combination therapies that include corticosteroids or anti-inflammatory agents.
• Investment in digital inhaler monitoring could provide real-world data, influencing label expansions.

Risks and Challenges

• Competitive pressure from established drugs like Spiriva and newer fixed-dose combinations.
• Regulatory hurdles in emerging markets.
• Cost containment policies may limit pricing flexibility.

Key Takeaways

• Clinical trials confirm STIOLTO RESPIMAT’s efficacy and safety for COPD management; no recent pivotal studies underway.
• The product holds an 8-10% market share in the COPD inhaler space, with steady sales growth driven by COPD prevalence.
• The global COPD therapeutics market is expanding at 4% CAGR, with STIOLTO projected to reach US$400–$500 million by 2025.
• Favorable reimbursement policies and guideline endorsements support future growth, but competitive dynamics pose risks.
• Expansion into emerging markets and integration of digital health tools could influence future market share.

FAQs

1. Are there any new clinical trials planned for STIOLTO RESPIMAT?
No currently active pivotal trials are announced. Ongoing observational studies are monitoring long-term safety and real-world effectiveness.

2. How does STIOLTO RESPIMAT compare to its competitors?
It offers similar efficacy to other LAMA/LABA fixed-dose combinations but has a smaller market share due to late market entry and intense competition from established therapies.

3. What is the main barrier to increased adoption of STIOLTO RESPIMAT?
Pricing and formulary placement limit access in some regions. Additionally, clinicians may prefer drugs with proven long-term safety data from larger, comparative trials.

4. Can market growth be sustained beyond 2025?
Growth may slow as market penetration approaches saturation in developed countries. However, expansion in emerging markets could extend growth opportunities.

5. What technological innovations could impact STIOLTO RESPIMAT’s market presence?
Enhanced inhaler devices with digital monitoring and integration with telehealth platforms may increase adherence and patient engagement.

---

References

[1] Global COPD therapeutics market size and growth data, MarketWatch, 2022.
[2] U.S. drug sales and prescription data, IQVIA, 2022.
[3] Regulatory approval timelines, FDA, EMA, 2018–2019.
[4] Market projections, Grand View Research, 2023.